Financial Performance - The company's operating revenue for 2020 was CNY 348.60 million, a decrease of 8.39% compared to the previous year [20]. - The net profit attributable to shareholders for 2020 was CNY 65.21 million, an increase of 6.34% year-over-year [20]. - The net profit after deducting non-recurring gains and losses was CNY 58.33 million, a decrease of 4.68% compared to the previous year [22]. - The net cash flow from operating activities increased by 62.04% year-over-year, reaching CNY 83.54 million [22]. - The net assets attributable to shareholders at the end of 2020 were CNY 740.06 million, an increase of 126.5% from the previous year [22]. - Basic and diluted earnings per share for 2020 were CNY 1.17, a decrease of 4.88% compared to the previous year [21]. - The company's total revenue for 2020 was 348,604,853.01 RMB, with quarterly revenues of 44,784,336.77 RMB, 93,982,001.62 RMB, 86,362,060.34 RMB, and 123,476,454.28 RMB respectively [25]. - The net profit attributable to shareholders for the year was 45,200,000.34 RMB, with a significant increase in the second half of the year, reaching 28,941,298.02 RMB in Q4 [25]. - The cash flow from operating activities showed a positive trend, with a net cash inflow of 40,707,742.38 RMB in Q4, compared to a cash outflow of -3,079,936.91 RMB in Q1 [25]. Research and Development - The proportion of R&D investment to operating revenue increased to 8.42%, up by 1.63 percentage points from the previous year [21]. - The company increased its R&D investment to ¥29,342,488.70 in 2020, a 13.50% increase from ¥25,851,396.54 in the previous year [66]. - Total R&D investment accounted for 8.42% of operating revenue, up from 6.79% in the previous year, reflecting a 1.63% increase [66]. - The company obtained 11 new patents and 7 new software copyrights during the reporting period, bringing the total to 70 patents and 27 software copyrights [64]. - The company is developing a medical trace element analyzer (ICP-MS) with features such as fast analysis speed, wide detection range, and high sensitivity, currently in application testing [66]. - The company is working on a project for rapid separation and detection of radioactive strontium, with a total investment of ¥70,000, aiming for automation and integration of the detection process [68]. - The company has developed a fully automated extraction and purification instrument for radioactive elements, which replaces manual operations to avoid radiation exposure [14]. - The company has integrated three types of sample pretreatment technologies into a single automated solution for customers [13]. Market and Industry Trends - The domestic market demand for experimental analysis instruments is increasing due to economic restructuring and heightened awareness of environmental protection and food safety [49]. - The company has established a competitive advantage in the experimental analysis instrument field, particularly in sample pretreatment instruments, which are among the few with a complete product line in China [50]. - Automation, integration, and intelligence are becoming trends in sample pretreatment technology, significantly reducing processing time and errors [52]. - The trend towards miniaturization and portability in sample pretreatment instruments is gaining attention from end users for field testing needs [54]. - Strategic emerging industries such as aerospace, new materials, and biomedicine are rapidly developing, expanding the application of experimental analysis instruments [58]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He [5]. - The board of directors and senior management have confirmed the accuracy and completeness of the annual report [4]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties [4]. - There are no violations of decision-making procedures regarding external guarantees [4]. - The company has not disclosed any special arrangements for corporate governance [4]. - The company is actively enhancing its internal control systems and governance to protect investor interests and comply with relevant regulations [91]. Shareholder and Dividend Policies - The company plans to distribute a cash dividend of 3.00 CNY per 10 shares, totaling 20,100,000.00 CNY, which represents 30.82% of the net profit attributable to shareholders for the year 2020 [5]. - The company has a cash dividend policy that mandates a minimum distribution of 10% of the distributable profit if certain conditions are met, with higher percentages for mature companies without major capital expenditures [149]. - The company has not made any changes to its cash dividend policy during the reporting period, ensuring the protection of minority investors' rights [149]. - The company will maintain its total distribution amount unchanged if there are changes in the total share capital before the implementation of the profit distribution plan [152]. Legal and Regulatory Matters - The company is currently involved in significant litigation related to a patent infringement dispute, which may impact its financial standing [192]. - The company was ordered to pay 2 million RMB as compensation in a patent infringement case related to a "sample digestion processing device" [193]. - The company has initiated an appeal to the Supreme People's Court regarding the aforementioned patent infringement ruling [193]. Strategic Initiatives and Future Plans - The company plans to continue expanding its presence in the medical testing and semiconductor detection fields as key future business directions [90]. - The company aims to enhance its R&D capabilities for mid-to-high-end scientific instruments, focusing on automation and multi-functional analysis technologies [139]. - Future plans include the development of new products in sample pretreatment and analytical testing instruments, such as gas and liquid sample mercury analyzers and mass spectrometers [142]. - The company plans to strengthen its marketing team to provide comprehensive laboratory system solutions, enhancing sales capabilities [144]. - The company aims to achieve continuous revenue growth by improving product quality and customer satisfaction through innovative technologies [139].

Financial Performance - Revenue for the first nine months decreased by 10.76% to CNY 225,128,398.73 compared to the same period last year[6]. - Net profit attributable to shareholders decreased by 7.90% to CNY 36,269,703.32 compared to the same period last year[6]. - Basic and diluted earnings per share decreased by 11.39% to CNY 0.70[7]. - The total comprehensive income for the first three quarters of 2020 was ¥36,286,894.32, down from ¥39,389,419.68 in the same period of 2019, a decrease of about 7.1%[31]. - The net profit for the first three quarters of 2020 was ¥22,135,954.97, compared to ¥18,432,347.41 in the same period of 2019, reflecting an increase of approximately 20.0%[35]. - The net profit for Q3 2020 was ¥16,772,315.61, compared to ¥13,507,594.53 in Q3 2019, reflecting an increase of about 24.4%[31]. - The net profit attributable to the parent company for Q3 2020 was ¥16,702,707.60, compared to ¥13,512,711.74 in Q3 2019, representing an increase of approximately 23.0%[32]. Assets and Liabilities - Total assets increased by 79.88% to CNY 808,801,045.94 compared to the end of the previous year[6]. - The company's total assets amounted to CNY 808,801,045.94, a significant increase from CNY 449,621,497.79 as of December 31, 2019, reflecting a growth of approximately 80%[24]. - The company's current assets reached CNY 713,294,448.07, compared to CNY 351,070,652.83 at the end of 2019, indicating a growth of about 103%[23]. - The company's total liabilities decreased to CNY 91,261,047.00 from CNY 122,109,807.86, a reduction of about 25%[24]. - Total liabilities decreased to ¥30,672,844.31 from ¥39,070,622.51 year-over-year, a decline of approximately 21.5%[28]. - Current liabilities reached CNY 119,595,723.56, including accounts payable of CNY 32,253,229.77 and short-term borrowings of CNY 7,684,566.70[44]. Cash Flow - Operating cash flow increased by 348.25% to CNY 42,830,583.18 for the period from January to September[6]. - The net cash flow from operating activities for the first three quarters of 2020 was CNY 42,830,583.18, significantly up from CNY 9,554,960.65 in the same period of 2019, indicating a growth of approximately 348.5%[38]. - Cash inflow from operating activities totaled CNY 272,368,049.30 for the first three quarters of 2020, slightly down from CNY 278,803,624.52 in 2019, a decrease of about 2.5%[37]. - The net cash flow from financing activities was CNY 339,388,632.12 in the first three quarters of 2020, compared to a net outflow of CNY 30,000,000.00 in the same period of 2019, marking a turnaround of CNY 369,388,632.12[38]. - The cash and cash equivalents at the end of the third quarter of 2020 amounted to CNY 566,412,908.85, a significant increase from CNY 151,426,736.46 at the end of the same quarter in 2019, reflecting a growth of approximately 273.5%[38]. Shareholder Information - The total number of shareholders reached 7,857 by the end of the reporting period[11]. - The largest shareholder, Beijing Laibotai Technology Management Consulting Co., Ltd., holds 36.09% of the shares[11]. - The equity attributable to shareholders rose to CNY 716,743,485.89, up from CNY 326,732,367.90, marking an increase of approximately 119%[25]. Research and Development - R&D expenditure as a percentage of revenue increased by 2.27 percentage points to 8.42%[7]. - Research and development expenses for Q3 2020 were ¥6,503,151.36, slightly up from ¥6,390,795.68 in Q3 2019, indicating a focus on innovation[31]. - Research and development expenses for Q3 2020 were ¥5,010,939.35, compared to ¥3,861,092.85 in Q3 2019, representing an increase of approximately 29.5%[34]. Other Financial Metrics - The company reported a net loss from non-operating activities of CNY 2,071,749.77[9]. - The company recognized a government subsidy income of RMB 485,390.03, a 986.6% increase compared to RMB 44,669.93 in the previous year, attributed to COVID-19 relief measures[18]. - The company incurred an estimated liability of RMB 2,000,000.00 for patent infringement litigation, a new expense not present in the previous year[18]. - The company reported a 63.5% reduction in financial expenses, amounting to RMB -504,569.09, primarily due to fluctuations in exchange rates[18].